In summary, we report the largest case series of daratumumab for the treatment of refractory autoimmune cytopenias. Our data demonstrate acceptable response rates (66%) with durable responses in most responders. Our report has several limitations including its retrospective nature and variable dosing schedules. Larger prospective studies are needed to study daratumumab for refractory autoimmune cytopenias.